Skip to content
Head to head

NeoGenomics vs Thermo Fisher Scientific

Side-by-side on the measures that matter, with a plain-English read. Full detail: NEO · TMO

Updated 9 minutes ago

1-year performance, rebased to 100

NEO +45.0%TMO +18.4%
It’s close.
NEOTMO
Snapshot
SectorDiagnostics & ResearchDiagnostics & Research
Last price14.82669.54
Change today-1.79%-2.79%
1-year return+39.8%+17.2%
Market cap$1.92B$248.08B
52-week range7.07 – 20.15434.50 – 727.56
Valuation
P/E (TTM)-61.7535.31
P/E percentile, own 5-yr range5th89th
P/B2.394.53
Dividend yield0.00%0.27%
Profitability & growth
EPS (TTM)-0.8417.74
Net profit (TTM)$-108.69M$6.57B
Revenue (TTM)$787.75M$47.35B
Provider revenue period date2026-09-292026-09-25
Revenue growth (YoY)+11.4%+9.1%
Gross margin44.8%41.1%
Operating margin-6.2%18.7%
Net margin-4.1%14.9%
Free cash flow (TTM)$-28.58M$7.60B
Provider cash-flow period date2026-09-292026-09-25
Ownership & sentiment
Institutional ownership116.1%94.1%
Insider activity (12mo)33 buy / 15 sell20 buy / 30 sell
Short interest (% of float)10.2%1.3%
Analyst consensus78% buy / 22% hold (9)88% buy / 12% hold (16)
Analyst price target$25 (+67%)$778 (+16%)
StockVane view
StockVane Quant RatingC (85)C (61)
Company
Employees2,500125,000
Founded19981956

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.